The FDA last month accepted the application for subcutaneous Leqembi for maintenance dosing, with a target action date of ...
Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical ...
OpenAI reveals a sleek rebrand featuring a refined logo, custom typeface, and cohesive design, blending human creativity with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback